Panitumumab-Induced Eruptive Seborrhoeic Keratosis in a Patient with Metastatic Colorectal Cancer

Authors

• Dimitra Koumaki Dermatology Department, University Hospital of Heraklion, PAGNI, Heraklion, Crete, Greece
• Sotirios Boumpoucheropoulos Medical Oncology Department, Agii Anargiri General Oncological Hospital of Kifisia, Athens, Greec
• Vasiliki Koumaki Department of Microbiology, Medical School of Athens, Greece
• Alexander Katoulis Department of Dermatology, Attikon University Hospital, Athens, Greece
• Georgia Pappas Medical Oncology Department, Agii Anargiri General Oncological Hospital of Kifisia, Athens, Greece
• Aikaterini Mantaka Department of Gastroenterology, University Hospital of Heraklion, PAGNI, Heraklion, Crete, Greece
• Konstantinos Krasagakis Dermatology Department, University Hospital of Heraklion, PAGNI, Heraklion, Crete, Greece

dkoumaki@yahoo.gr

Keywords

Abstract

Objectives: Agents targeting the epidermal growth factor receptor (EGFR)-mediated signalling pathway are increasingly being used for the treatment of advanced lung, pancreatic, colorectal and head and neck cancers.
Case presentation: Here, we report the first case of eruptive seborrhoeic keratosis following panitumumab treatment, an anti-EGFR monoclonal antibody, in a 73-year-old patient with stage 4 (IV) colorectal cancer with hepatic metastasis.
Conclusion: While panitumumab is an emerging therapy for RAS wild-type metastatic colorectal cancer, physicians should consider panitumumab as a potential cause of eruptive seborrhoeic keratosis.